T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?

Abstract

Pancreatic disorders cause a broad spectrum of clinical diseases, mainly including acute and chronic pancreatitis and pancreatic cancer, and are associated with high global rates of morbidity and mortality. Unfortunately, the pathogenesis of pancreatic disease remains obscure, and there is a lack of specific treatments. T lymphocytes (T cells) play a vital role in the adaptive immune systems of multicellular organisms. During pancreatic disease development, local imbalances in T-cell subsets in inflammatory and tumor environments and the circulation have been observed. Furthermore, agents targeting T cells have been shown to reverse the natural course of pancreatic diseases. In this review, we have discussed the clinical relevance of T-cell alterations as a potential outcome predictor and the underlying mechanisms, as well as the present status of immunotherapy targeting T cells in pancreatitis and neoplasms. The breakthrough findings summarized in this review have important implications for innovative drug development and the prospective use of immunotherapy for pancreatitis and pancreatic cancer.

• Authors: Qi Zhou, Xufeng Tao, Shilin Xia, Fangyue Guo, Chen Pan, Hong Xiang, Dong Shang
• Journal: Frontiers in oncology (Front Oncol) Vol. 10 Pg. 382 ( 2020) ISSN: 2234-943X [Print] Switzerland
• PMID: 32266154 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020 Zhou, Tao, Xia, Guo, Pan, Xiang and Shang.